RBRocky Lee Baker

Rocky Lee Baker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rocky Lee Baker has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Kathryn Haskins

    Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO

    16 shared publications
  • Thomas Delong

    Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

    9 shared publications
  • Brenda Bradley

    Department of Immunology and Microbiology, University of Colorado School of Medicine at Denver, Aurora, CO

    7 shared publications
  • Gene Barbour

    Department of Immunology and Microbiology, University of Colorado School of Medicine at Denver, Aurora, CO

    7 shared publications
  • Kathryn Haskins

    Department of Immunology and Microbiology, University of Colorado School of Medicine

    6 shared publications
  • Thomas Delong

    Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO

    6 shared publications

Latest Publications

  • Open Access

    A novel region of the insulin B9–23 sequence is targeted by a HIP-reactive diabetogenic T cell clone

    by Janet M. Wenzlau, Kaitlin Mangold, Kelli Nicholson, Mylinh Dang, Anita C. Hohenstein, Kelly S. Douglas, James E. DiLisio, Roger Powell, Thomas Delong, Kathryn Haskins, et al.

    Type 1 Diabetes (T1D) is an organ-specific autoimmune disease in which T cells are major drivers, leading to the destruction of beta-cells and insulin deficiency. Although the B-chain of insulin is a critical target for islet-reactive CD4 T cells, the native sequence is poorly antigenic and in vivo , insulin elicits only a weak Th1 response. We previously reported that post-translational modification of proinsulin through hybrid insulin peptide (HIP) formation leads to the synthesis of potent epitopes for islet-reactive CD4 T cells, and that cathepsin D (catD), a protease present in beta-cells, can mediate the formation of HIPs through a transpeptidation process. In the present study, we defined the specificity of catD for the insulin B-chain and show a high specificity for proteolytic cleavage following the disease-critical tyrosine 16 residue. We therefore hypothesized that HIP formation occurs at this amino acid. We designed a panel of HIPs containing insB 9–16 fragments linked to different secretory granule proteins and challenged splenocytes isolated from diabetic NOD mice with insB 9–16 HIPs; ELISPOT analysis showed elevated inflammatory responses to several peptides. Among this panel of HIPs, we identified the 2.40HIP, a fusion peptide between insB 9–16 and the C-peptide, as a potent epitope recognized by PD12-2.40, a diabetogenic CD4 T cell clone isolated from the islets of a 12-week-old NOD mouse. These results define a new antigenic region of the insulin B:9–23 peptide and demonstrate that this sequence of the B-chain becomes dramatically more antigenic when post-translationally modified through HIP formation.


  • Open Access

    Antigen-specific immunotherapy with a CD4+ T cell neoepitope restrains CD8+ T cell differentiation in murine pancreatic islet grafts

    by James E. DiLisio, K. Scott Beard, Tobias Neef, Stephen D. Miller, Janet M. Wenzlau, Maki Nakayama, Marc A. D’ANtonio, Braxton L. Jamison, Kelli S. Nicholson, Rocky L. Baker, et al.

    Pancreatic islet transplantation offers a potential cure for autoimmune type 1 diabetes (T1D) but requires immunosuppression to prevent recurrent, T cell-mediated autoimmunity. Antigen-specific immunotherapy is a targeted alternative that induces peripheral tolerance in autoreactive T cells without broad immunosuppression. Tolerance induction with antigen-specific therapies may induce dominant tolerance, extending to T cell clones other than those targeted by the therapy. However, the mechanism of this suppression remains unclear. Using pancreatic islet transplantation in NOD mice, we show that induction of tolerance to a CD4+ T cell hybrid insulin peptide neoepitope reprograms the fate of antigen-specific CD8+ T cells within the grafts. Induction of tolerance to a single hybrid insulin peptide transiently protected islet grafts from autoimmune destruction, and graft survival could be extended with continued therapeutic dosing. Treatment limited a cytolytic/interferon-stimulated differentiation program in antigen-specific CD8+ T cells and reduced TCR avidity within grafts. This was mediated in part by IL-10-producing regulatory CD4+ T cells that suppressed dendritic cell activation. IL-10 blockade reversed these effects, restoring CD8+ T cell differentiation, as well as the licensing of dendritic cells. These findings reveal an IL-10-dependent mechanism by which CD4+ T cell-targeted immunotherapy restrains pathogenic CD8+ T cell fates through the suppression of dendritic cells in islet grafts.

  • Strategic Reduction of Hybrid Insulin Peptide Formation Significantly Delays Diabetes Onset in NOD Mice

    by Jason Groegler, Kaitlin Mangold, Kelli Nicholson, Mylinh Dang, Janet Wenzlau, K. Scott Beard, Anita Hohenstein, Roger Powell, Rocky Baker, Kathryn Haskins, et al.

    Type 1 diabetes (T1D) is characterized by autoimmune destruction of insulin-producing β-cells. Recent evidence has implicated hybrid insulin peptides (HIPs) as targets of autoreactive CD4 T cells in human T1D patients and as critical autoantigens recognized by diabetogenic T cells in nonobese diabetic (NOD) mice. HIPs form within pancreatic islets through cross-linking reactions between proinsulin fragments and various β-cell peptides. In the NOD mouse model, highly pathogenic CD4 T cells specifically target HIPs generated through transpeptidation mediated by cathepsin D (CatD). These disease-relevant HIPs consistently incorporate a C-peptide fragment terminating in a critical leucine residue that binds to other β-cell peptides. In vitro experiments demonstrated that substituting isoleucine for this leucine residue in human C-peptide inhibited CatD-mediated HIP formation. To investigate the in vivo significance of this finding, we engineered NOD mice carrying a leucine-to-isoleucine mutation in the insulin 2 gene (NOD INS2I/I). Mass spectrometric analysis revealed significantly reduced HIP formation in islets from NOD INS2I/I mice. Significantly decreased activation of HIP-reactive T cells to islets from these mice was also observed. Furthermore, the NOD INS2I/I mice showed significantly delayed diabetes onset, with 43% remaining disease-free at 1 year compared with only 10% of wild-type NOD controls. These findings implicate HIPs as key mediators in T1D pathogenesis and demonstrate that targeted disruption of HIP formation significantly alters disease progression. Inhibiting CatD-mediated transpeptidation represents a promising therapeutic approach for preventing or delaying T1D onset in genetically susceptible individuals. Article Highlights: Hybrid insulin peptides (HIPs) have been identified as targets of autoreactive T cells in type 1 diabetes, although their causal role in disease pathogenesis has remained unclear. We demonstrated that a single leucine-to-isoleucine substitution in insulin C-peptide significantly disrupts cathepsin D–mediated HIP formation in nonobese diabetic (NOD) mouse islets. NOD mice engineered with this precise modification (NOD INS2I/I) showed significantly reduced HIP content, decreased T-cell reactivity, and significantly delayed diabetes onset (43% disease-free at 1 year vs. 10% in controls). These findings establish a mechanistic link between HIP formation and disease progression, revealing cathepsin D–mediated transpeptidation as a potential therapeutic target for intervention in at-risk individuals.


  • Novel T-Cell Reactivities to Hybrid Insulin Peptides in Islet Autoantibody–Positive At-Risk Individuals

    by Anita C. Hohenstein, Joylynn B. Gallegos, Mylinh Dang, Jason Groegler, Hali Broncucia, Fatima A. Tensun, Kathleen Waugh, Fran Dong, Eddie A. James, Cate Speake, et al.

    Type 1 diabetes (T1D) is an autoimmune disease mediated by autoreactive T cells. Our studies indicate that CD4 T cells reactive to hybrid insulin peptides (HIPs) play a critical role in T-cell–mediated β-cell destruction. We have shown that HIPs form in human islets between fragments of the C-peptide and cleavage products of secretory granule proteins. To identify T-cell specificities contributing to T1D pathogenesis, we tested T-cell reactivity from T1D patients or healthy control individuals using an IFN-γ enzyme-linked immunosorbent spot assay against a library of 240 C-peptide HIPs. We observed elevated T-cell responses to peptide pools containing HIPs that form at the amino acid residues G15, A18, and L26 of C-peptide. In a second cohort of healthy control individuals, at-risk individuals, and T1D patients, T-cell reactivity to HIPs forming at these three residues was monitored. Results indicate that, prior to clinical onset of T1D, there were significantly elevated responses to multiple pools of HIPs, and the magnitude of T-cell reactivity to HIPs forming at residue A18 of the C-peptide was increased. Overall, our study identifies new T-cell specificities in at-risk individuals and indicates that T-cell reactivity to HIPs can be observed before T1D onset. Article Highlights: We identified a new region of the C-peptide that is targeted by hybrid insulin peptide (HIP)-reactive T cells in patients with type 1 diabetes and antibody-positive individuals. Antibody-positive individuals exhibited robust and broad T cell responses to HIPs. When compared to healthy control individuals, a significantly higher percentage of antibody-positive individuals who progressed to a higher stage of type 1 diabetes displayed responses to HIPs.


  • Open Access

    Characterization of Human CD4 T Cells Specific for a C-Peptide/C-Peptide Hybrid Insulin Peptide

    by Timothy A. Wiles, Anita Hohenstein, Laurie G. Landry, Mylinh Dang, Roger Powell, Perrin Guyer, Eddie A. James, Maki Nakayama, Kathryn Haskins, Thomas Delong, et al.

    Hybrid Insulin Peptides (HIPs), which consist of insulin fragments fused to other peptides from β-cell secretory granule proteins, are CD4 T cell autoantigens in type 1 diabetes (T1D). We have studied HIPs and HIP-reactive CD4 T cells extensively in the context of the non-obese diabetic (NOD) mouse model of autoimmune diabetes and have shown that CD4 T cells specific for HIPs are major contributors to disease pathogenesis. Additionally, in the human context, HIP-reactive CD4 T cells can be found in the islets and peripheral blood of T1D patients. Here, we performed an in-depth characterization of the CD4 T cell response to a C-peptide/C-peptide HIP (HIP11) in human T1D. We identified the TCR expressed by the previously-reported HIP11-reactive CD4 T cell clone E2, which was isolated from the peripheral blood of a T1D patient, and determined that it recognizes HIP11 in the context of HLA-DQ2. We also identified a HIP11-specific TCR directly in the islets of a T1D donor and demonstrated that this TCR recognizes a different minimal epitope of HIP11 presented by HLA-DQ8. We generated and tested an HLA-DQ2 tetramer loaded with HIP11 that will enable direct ex vivo interrogation of CD4 T cell responses to HIP11 in human patients and control subjects. Using mass spectrometric analysis, we confirmed that HIP11 is present in human islets. This work represents an important step in characterizing the role of CD4 T cell responses to HIPs in human T1D.


  • Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01

    by David Arribas-Layton, Perrin Guyer, Thomas Delong, Mylinh Dang, I-Ting Chow, Cate Speake, Carla J. Greenbaum, William W. Kwok, Rocky L. Baker, Kathryn Haskins, et al.

    T cells isolated from the pancreatic infiltrates of nonobese diabetic mice have been shown to recognize epitopes formed by the covalent cross-linking of proinsulin and secretory granule peptides. Formation of such hybrid insulin peptides (HIPs) was confirmed through mass spectrometry, and responses to HIPs were observed among the islet-infiltrating T cells of pancreatic organ donors and in the peripheral blood of individuals with type 1 diabetes (T1D). However, questions remain about the prevalence of HIP-specific T cells in humans, the sequences they recognize, and their role in disease. We identified six novel HIPs that are recognized in the context of DRB1*04:01, discovered by using a library of theoretical HIP sequences derived from insulin fragments covalently linked to one another or to fragments of secretory granule proteins or other islet-derived proteins. We demonstrate that T cells that recognize these HIPs are detectable in the peripheral blood of subjects with T1D and exhibit an effector memory phenotype. HIP-reactive T-cell clones produced Th1-associated cytokines and proliferated in response to human islet preparations. These results support the relevance of HIPs in human disease, further establishing a novel posttranslational modification that may contribute to the loss of peripheral tolerance in T1D.


  • Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes

    by Rocky L. Baker, Braxton L. Jamison, Kathryn Haskins

    Purpose of review: The current review covers recent advances in our knowledge of the newest autoantigen neo-epitopes in type 1 diabetes (T1D): hybrid insulin peptides or HIPs. These ligands for autoreactive T cells are formed by peptide fusion, a novel posttranslational modification process that we first reported in 2016. Recent findings: Two major HIPs in the nonobese diabetic mouse model, ligands for diabetogenic CD4 T-cell clones, have been incorporated into tetramers and used to track HIP-reactive T cells during progression of disease. HIPs have also been used in strategies for induction of antigen-specific tolerance and show promise for delaying or reversing disease in the nonobese diabetic mouse. Importantly, CD4 T cells reactive to various HIPs have been detected in the islets and peripheral blood mononuclear cell of T1D patients and newly developed human T-cell clones are being employed to gather more data on the phenotype and function of HIP-reactive T cells in patients. Summary: These new hybrid insulin peptide epitopes may provide the basis for establishing autoreactive T cells as biomarkers of disease and as potential tolerogens for treatment of T1D.


  • Open Access

    Nanoparticles Containing an Insulin–ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells

    by Braxton L. Jamison, Tobias Neef, Andrew Goodspeed, Brenda Bradley, Rocky L. Baker, Stephen D. Miller, Kathryn Haskins

    CD4 T cells play a critical role in promoting the development of autoimmunity in type 1 diabetes. The diabetogenic CD4 T cell clone BDC-2.5, originally isolated from a NOD mouse, has been widely used to study the contribution of autoreactive CD4 T cells and relevant Ags to autoimmune diabetes. Recent work from our laboratory has shown that the Ag for BDC-2.5 T cells is a hybrid insulin peptide (2.5HIP) consisting of an insulin C-peptide fragment fused to a peptide from chromogranin A (ChgA) and that endogenous 2.5HIP-reactive T cells are major contributors to autoimmune pathology in NOD mice. The objective of this study was to determine if poly(lactide-co-glycolide) (PLG) nanoparticles (NPs) loaded with the 2.5HIP Ag (2.5HIP-coupled PLG NPs) can tolerize BDC-2.5 T cells. Infusion of 2.5HIP-coupled PLG NPs was found to prevent diabetes in an adoptive transfer model by impairing the ability of BDC-2.5 T cells to produce proinflammatory cytokines through induction of anergy, leading to an increase in the ratio of Foxp3+ regulatory T cells to IFN-γ+ effector T cells. To our knowledge, this work is the first to use a hybrid insulin peptide, or any neoepitope, to re-educate diabetogenic T cells and may have significant implications for the development of an Ag-specific therapy for type 1 diabetes patients. Key Points A hybrid insulin peptide (HIP) neoepitope can tolerize diabetogenic T cells. Tolerance induction promotes T cell anergy and increases Treg/Teff ratio. HIPs are potential therapeutics in type 1 diabetes.


  • Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes

    by Rocky L. Baker, Marynette Rihanek, Anita C. Hohenstein, Maki Nakayama, Aaron Michels, Peter A. Gottlieb, Kathryn Haskins, Thomas Delong

    We recently established that hybrid insulin peptides (HIPs) are present in human islets and that T cells reactive to HIPs are found in the residual islets of organ donors with type 1 diabetes (T1D). Here, we investigate whether HIP-reactive T cells are indicative of ongoing autoimmunity in patients with T1D. We used interferon-γ enzyme-linked immune absorbent spot analyses on peripheral blood mononuclear cells (PBMCs) to determine whether patients with new-onset T1D or control subjects displayed T-cell reactivity to a panel of 16 HIPs. We observed that nearly one-half of the patients responded to one or more HIPs. Responses to four HIPs were significantly elevated in patients with T1D but not in control subjects. To characterize the T cells reactive to HIPs, we used a carboxyfluorescein succinimidyl ester–based assay to clone T cells from PBMCs. We isolated six nonredundant, antigen-specific T-cell clones, most of which reacting to their target HIPs in the low nanomolar range. One T-cell clone was isolated from the same patient on two different blood draws, indicating persistence of this T-cell clone in the peripheral blood. This work suggests that HIPs are important target antigens in human subjects with T1D and may play a critical role in disease.


  • Increased β-cell proliferation before immune cell invasion prevents progression of type 1 diabetes

    by Ercument Dirice, Sevim Kahraman, Dario F. De Jesus, Abdelfattah El Ouaamari, Giorgio Basile, Rocky L. Baker, Burcu Yigit, Paul D. Piehowski, Mi-Jeong Kim, Alexander J. Dwyer, et al.

    Type 1 diabetes (T1D) is characterized by pancreatic islet infiltration by autoreactive immune cells and a nearly complete loss of β cells1. Restoration of insulin-producing β cells coupled with immunomodulation to suppress the autoimmune attack has emerged as a potential approach to counter T1D2,3,4. Here we report that enhancing β-cell mass early in life, in two models of female non-obese diabetic (NOD) mice, results in immunomodulation of T cells, reduced islet infiltration and lower β-cell apoptosis, which together protect them from developing T1D. The animals displayed altered β-cell antigens; islet transplantation studies showed prolonged graft survival in the NOD-liver-specific insulin receptor knockout (LIRKO) model. Adoptive transfer of splenocytes from NOD-LIRKO mice prevented development of diabetes in prediabetic NOD mice. A substantial increase in the splenic CD4+CD25+Foxp3+ regulatory T cell (Treg) population was observed to underlie the protected phenotype since Treg-cell depletion rendered NOD-LIRKO mice diabetic. An increase in Treg cells coupled with activation of transforming growth factor-β/SMAD family member 3 signalling pathway in pathogenic T cells favoured reduced ability to kill β cells. These data support a previously unidentified observation that initiating β-cell proliferation, alone, before islet infiltration by immune cells alters the identity of β cells, decreases pathological self-reactivity of effector T cells and increases Treg cells to prevent the progression of T1D.